AI Article Synopsis
- m unable to access external links directly, but if you can provide me with the main details or a brief summary of the text, I'd be happy to help you create a 3-bullet synopsis from it!
Article Abstract
https://bit.ly/3Z5AZJ3
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525346 | PMC |
| http://dx.doi.org/10.1183/13993003.01483-2024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of Sotatercept Across Ranges of Cardiac Index in Patients with Pulmonary Arterial Hypertension: A Pooled Analysis of PULSAR and STELLAR.
J Heart Lung Transplant
December 2024
Department of Internal Medicine, Justus-Liebig-University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany.
Background: This analysis compared effects of the activin signaling inhibitor, sotatercept, across pulmonary arterial hypertension (PAH) subgroups stratified by baseline cardiac index (CI).
Methods: Pooled data from PULSAR (N=106; NCT03496207) and STELLAR (N=323; NCT04576988) were analyzed using two different CI thresholds, < and ≥ 2.0 L/min/m or 2.
Effect of sotatercept on circulating proteomics in pulmonary arterial hypertension.
Eur Respir J
October 2024
Université Paris-Saclay, Hypertension Pulmonaire: Physiopathology and Innovation Thérapeutique, HPPIT, Faculté de Médecine, Le Kremlin-Bicêtre, France
https://bit.ly/3Z5AZJ3
View Article and Find Full Text PDFArticle Synopsis
- The STELLAR trial tested the drug sotatercept, showing it improved walking distance and other health measures in patients with pulmonary arterial hypertension (PAH).
- Data from right heart catheterization and echocardiography were analyzed over 24 weeks to assess the drug's effects on heart and lung parameters.
- Results indicated significant reductions in pulmonary artery pressure and resistance, along with improvements in right heart function, indicating sotatercept's potential effectiveness for PAH patients.
Sotatercept as a next-generation therapy for pulmonary arterial hypertension: insights from the STELLAR trial.
Cardiovasc Res
December 2023
Pulmonary Circulation Centre, Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, Prądnicka 80, 31-202 Kraków, Poland.
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
N Engl J Med
April 2023
From the Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Member of the German Center for Lung Research, Biomedical Research in End-Stage and Obstructive Lung Disease Hannover, Hannover (M.M.H., K.M.O.), the Department of Internal Medicine, Universities of Giessen and Marburg Lung Center, Institute for Lung Health, Cardio-Pulmonary Institute, Member of the German Center for Lung Research, Giessen (H.A.G.), Thoraxklinik-Heidelberg and the German Center for Lung Research, Heidelberg (E.G.), and the Department of Cardiology, Heart Center, University Hospital Cologne, Cologne (S.R.) - all in Germany; the University of Colorado, Anschutz Medical Campus, Aurora (D.B.B.); the National Heart and Lung Institute, Imperial College London, London (J.S.R.G.); George Washington University, Washington, DC (M.G.-M.); the University of Michigan, Ann Arbor (V.V.M.); Tufts Medical Center (I.R.P.) and Brigham and Women's Hospital (A.B.W.) - both in Boston; Instituto do Coração, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo (R.S.), and Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre (G.M.) - both in Brazil; the Pulmonary Circulation Center, Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, John Paul II Hospital in Krakow, Krakow, Poland (G.K.); Merck (Y.X., J.K.) and Acceleron Pharma (B.M., M.F., J.B., J.O.P.) - both in Rahway, NJ; and Université Paris-Saclay, INSERM Unité Mixte de Recherche en Santé 999, Hôpital Bicêtre (Assistance Publique-Hôpitaux de Paris), Le Kremlin-Bicêtre, France (M.H.).
Article Synopsis
- * A phase 3 clinical trial tested sotatercept against a placebo in adults with PAH who were already on stable therapy, focusing on improvements in exercise capacity measured by walking distance over a 24-week period, along with several secondary health measures.
- * Results from the trial indicated that patients taking sotatercept had a significant improvement in their 6-minute walk distance compared to those on placebo, showing a median increase of 34.4 meters versus just
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!